Published: January 21, 2026 at 12:46 pm
A Cheshire-based MedTech has secured £4.5 million of investment and grant funding to help transform treatment for glioblastoma (GBM) and potentially extend thousands of lives each year.
QV Bioelectronics, based at Alderley Park, is said to have developed a world-first implantable device designed to improve outcomes for patients with hard-to-treat GBM.
Cancer Research UK says glioblastoma accounted for around 32% of all brain tumours diagnosed in England between 1995 and 2017.
It is the most common type of primary brain cancer in adults, affecting around 2,200 UK adults each year and is known for being fast-growing and difficult to treat.